Antibodies screening

PreclinicalBiologic

UUniversity Hospital, Bordeaux

Antibodies screening is one of 8 biologic programs targeting Asthenia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AstheniaActive, not recruiting

AstheniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Asthenia

#DrugCompanyPhaseTrials

Ritalin

Novartis

Phase 3

1 2

Rysodeg

Rayos

1 4

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Phase 2

1 5

Prospekta

MMateria Medica Holding

Phase 3

1 6

Ranquilon

VValenta Pharm JSC

Phase 3

1 7

Eptacog Alfa

Novo Nordisk

Preclinical

1 8

Antibodies screening

UUniversity Hospital, Bordeaux

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthenia1 trial

Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)

Completed·UUniversity Hospital, Bordeaux·N/A·NCT04595617·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antibodies screening. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antibodies screening compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antibodies screening. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Bordeaux company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Bordeaux

Antibodies screening

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Asthenia1 trial

References

Drug Info

Quick Facts

Related News